Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,957,808
  • Shares Outstanding, K 107,700
  • Annual Sales, $ 5,872 M
  • Annual Income, $ 1,199 M
  • 36-Month Beta 1.40
  • Price/Sales 5.79
  • Price/Cash Flow 19.42
  • Price/Book 5.05

Price Performance

See More
Period Period Low Period High Performance
1-Month
291.10 +8.31%
on 05/23/18
320.69 -1.68%
on 06/15/18
+14.85 (+4.94%)
since 05/15/18
3-Month
281.89 +11.85%
on 05/09/18
352.59 -10.58%
on 03/19/18
-19.63 (-5.86%)
since 03/15/18
52-Week
281.89 +11.85%
on 05/09/18
543.55 -41.99%
on 06/22/17
-154.20 (-32.84%)
since 06/15/17

Most Recent Stories

More News
Watch for Regeneron Pharm to Potentially Pullback After Gaining 2.35% Yesterday

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $307.58 to a high of $315.81. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high...

REGN : 315.30 (-0.12%)
The Committee of prominent health researchers and Nobel laureates renames the Prix Galien Pro Bono Humanum Award to recognize the global health leadership of Dr. Roy Vagelos

The Prix Galien USA Committee announced today that the Prix Galien Pro Bono Humanum Award for individual service to improve the state of human health will be renamed in honor of Dr. P. Roy Vagelos, Retired...

REGN : 315.30 (-0.12%)
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.

AXON : 3.79 (+1.34%)
REGN : 315.30 (-0.12%)
AMGN : 185.01 (-0.42%)
ALXN : 121.52 (+1.13%)
BIIB : 305.03 (-0.21%)
Alnylam Reports Positive Data on Lumasiran in Renal Disease

Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.

MDCO : 36.90 (+0.57%)
ALNY : 107.80 (+0.69%)
REGN : 315.30 (-0.12%)
SNY : 39.94 (+2.46%)
Blog Exposure - Regeneron Inks Five-Year Collaboration Deal with Zoetis to Discover Antibody Therapies in Animal Health

LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Regeneron Pharma, Inc. (NASDAQ: ) ("Regeneron"), all you need to do is sign up now by clicking the following...

ZTS : 89.20 (+1.19%)
REGN : 315.30 (-0.12%)
Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO

The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.

CELG : 78.08 (-0.40%)
SRPT : 102.29 (+3.55%)
VRTX : 155.02 (+0.02%)
GILD : 70.23 (-1.29%)
REGN : 315.30 (-0.12%)
AMGN : 185.01 (-0.42%)
BIIB : 305.03 (-0.21%)
Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Zoetis Inc. (NYSE:ZTS) today announced a five-year collaboration to research the use of Regeneron's monoclonal antibody therapeutics in animals and discover...

ZTS : 89.20 (+1.19%)
REGN : 315.30 (-0.12%)
Mylan (MYL) Gets FDA Approval for Biosimilar of Neulasta

Mylan (MYL) and partner Biocon get a significant boost with the FDA approval for Fulphila, a biosimilar of Amgen's Neulasta.

MYL : 39.00 (-1.29%)
MNTA : 21.90 (-4.78%)
REGN : 315.30 (-0.12%)
AMGN : 185.01 (-0.42%)
New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma

The New England Journal of Medicine (NEJM) today published pivotal data from two trials evaluating cemiplimab in advanced cutaneous squamous cell carcinoma (CSCC). The results were also presented at the...

SAN : 5.45 (-1.98%)
REGN : 315.30 (-0.12%)
SNY : 39.94 (+2.46%)
New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma

Patients treated with cemiplimab experienced robust anti-tumor effects

REGN : 315.30 (-0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 325.78
1st Resistance Point 320.54
Last Price 315.30
1st Support Level 310.21
2nd Support Level 305.12

See More

52-Week High 543.55
Fibonacci 61.8% 443.60
Fibonacci 50% 412.72
Fibonacci 38.2% 381.84
Last Price 315.30
52-Week Low 281.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar